<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2025//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_250101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">41024792</PMID><DateCompleted><Year>2025</Year><Month>09</Month><Day>30</Day></DateCompleted><DateRevised><Year>2025</Year><Month>09</Month><Day>30</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">1948-9366</ISSN><JournalIssue CitedMedium="Print"><Volume>17</Volume><Issue>9</Issue><PubDate><Year>2025</Year><Month>Sep</Month><Day>27</Day></PubDate></JournalIssue><Title>World journal of gastrointestinal surgery</Title><ISOAbbreviation>World J Gastrointest Surg</ISOAbbreviation></Journal><ArticleTitle>Treatment of human umbilical cord-derived mesenchymal stem cells for hepatitis B virus-associated decompensated liver cirrhosis: A clinical trial.</ArticleTitle><Pagination><StartPage>109980</StartPage><MedlinePgn>109980</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">109980</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.4240/wjgs.v17.i9.109980</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Large number of decompensated liver cirrhosis patients in China have been diagnosed with hepatitis B virus (HBV). Human umbilical cord-derived mesenchymal stem cells (hUC-MSCs) can possibly cure decompensated liver cirrhosis because of their self-renewal and multidirectional differentiation potential.</AbstractText><AbstractText Label="AIM" NlmCategory="OBJECTIVE">To explore the safety and effect of treating liver cirrhosis with HBV by hUC-MSCs.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">Twenty-four participants were recruited, divided into 3 groups, and injected with different amounts of hUC-MSCs <i>via</i> the peripheral vein. Therapy was administered 3 times. A 24-week follow-up examination of each patient's liver function, coagulation function, general condition, and immune system was performed. Adverse events were also recorded. A 2-year survival assessment was subsequently performed.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Infusion therapy rapidly improved liver function. Serum albumin transiently increased on days 57 and 85 but returned to baseline by day 169, while prothrombin time activity demonstrated sustained improvement from day 29 through day 169. Interleukin-8 levels decreased persistently throughout treatment. All dosage groups achieved 100% 6-month survival; 2-year survival rates were 66.7% (low-dose), 100% (medium-dose), and 87.5% (high-dose). The interaction between dosage and efficacy was weak. Notably, the improvement in liver function was statistically significant and sustained for almost 3 months, suggesting clinically meaningful therapeutic durability.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">hUC-MSCs can be considered a safe treatment for patients with decompensated liver cirrhosis associated with HBV. However, larger-scale randomized controlled trials are needed to prove its therapeutic effect.</AbstractText><CopyrightInformation>&#xa9;The Author(s) 2025. Published by Baishideng Publishing Group Inc. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Qin</LastName><ForeName>Xian</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>Department of Hepatobiliary and Pancreatic Surgery, Zhongnan Hospital of Wuhan University, Wuhan 430000, Hubei Province, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chen</LastName><ForeName>Jing</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Internal Medicine and Geriatrics, Zhongnan Hospital of Wuhan University, Wuhan 430000, Hubei Province, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhang</LastName><ForeName>Hua-Ni</ForeName><Initials>HN</Initials><AffiliationInfo><Affiliation>Hubei Provincial Clinical Research Center for Umbilical Cord Blood Hematopoietic Stem Cells, Taihe Hospital, Hubei University of Medicine, Shiyan 442000, Hubei Province, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Pharmacy, Shiyan Hospital of Integrated Traditional Chinese and Western Medicine, Shiyan 442000, Hubei Province, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Du</LastName><ForeName>Li</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Department of Hepatobiliary and Pancreatic Surgery, Zhongnan Hospital of Wuhan University, Wuhan 430000, Hubei Province, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ma</LastName><ForeName>Yan</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Hepatobiliary and Pancreatic Surgery, Zhongnan Hospital of Wuhan University, Wuhan 430000, Hubei Province, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Yi</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Hepatobiliary and Pancreatic Surgery, Zhongnan Hospital of Wuhan University, Wuhan 430000, Hubei Province, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lu</LastName><ForeName>Yu</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Hepatobiliary and Pancreatic Surgery, Zhongnan Hospital of Wuhan University, Wuhan 430000, Hubei Province, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Ya-Ting</ForeName><Initials>YT</Initials><AffiliationInfo><Affiliation>Department of Hepatobiliary and Pancreatic Surgery, Zhongnan Hospital of Wuhan University, Wuhan 430000, Hubei Province, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wu</LastName><ForeName>Liu-Fang</ForeName><Initials>LF</Initials><AffiliationInfo><Affiliation>Department of Hepatobiliary and Pancreatic Surgery, Zhongnan Hospital of Wuhan University, Wuhan 430000, Hubei Province, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yu</LastName><ForeName>Zi-Hui</ForeName><Initials>ZH</Initials><AffiliationInfo><Affiliation>Department of Hepatobiliary and Pancreatic Surgery, Zhongnan Hospital of Wuhan University, Wuhan 430000, Hubei Province, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hu</LastName><ForeName>Meng-Jing</ForeName><Initials>MJ</Initials><AffiliationInfo><Affiliation>Department of Hepatobiliary and Pancreatic Surgery, Zhongnan Hospital of Wuhan University, Wuhan 430000, Hubei Province, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Li-Jun</ForeName><Initials>LJ</Initials><AffiliationInfo><Affiliation>Department of Internal Medicine and Geriatrics, Zhongnan Hospital of Wuhan University, Wuhan 430000, Hubei Province, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Liao</LastName><ForeName>Bo</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Department of Hepatobiliary and Pancreatic Surgery, Zhongnan Hospital of Wuhan University, Wuhan 430000, Hubei Province, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Zhen</ForeName><Initials>Z</Initials><AffiliationInfo><Affiliation>Department of Hepatobiliary and Pancreatic Surgery, Zhongnan Hospital of Wuhan University, Wuhan 430000, Hubei Province, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yang</LastName><ForeName>Zhi-Yong</ForeName><Initials>ZY</Initials><AffiliationInfo><Affiliation>Department of Hepatobiliary and Pancreatic Surgery, Zhongnan Hospital of Wuhan University, Wuhan 430000, Hubei Province, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Pancreatic Surgery Center, Clinical Medicine Research Center for Minimally Invasive Procedure of Hepatobiliary and Pancreatic Diseases of Hubei Province, Zhongnan Hospital of Wuhan University, Wuhan 430071, Hubei Province, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Kun</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Department of Hepatobiliary and Pancreatic Surgery, Zhongnan Hospital of Wuhan University, Wuhan 430000, Hubei Province, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yuan</LastName><ForeName>Yu-Feng</ForeName><Initials>YF</Initials><AffiliationInfo><Affiliation>Department of Hepatobiliary and Pancreatic Surgery, Zhongnan Hospital of Wuhan University, Wuhan 430000, Hubei Province, China. yuanyf1971@whu.edu.cn.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016430">Clinical Trial</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>World J Gastrointest Surg</MedlineTA><NlmUniqueID>101532473</NlmUniqueID></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Clinical trial</Keyword><Keyword MajorTopicYN="N">Decompensated liver cirrhosis</Keyword><Keyword MajorTopicYN="N">Hepatitis virus B</Keyword><Keyword MajorTopicYN="N">Liver function</Keyword><Keyword MajorTopicYN="N">Umbilical cord-derived mesenchymal stem cells</Keyword></KeywordList><CoiStatement>Conflict-of-interest statement: All the authors report no relevant conflicts of interest for this article.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2025</Year><Month>5</Month><Day>27</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2025</Year><Month>6</Month><Day>25</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2025</Year><Month>7</Month><Day>28</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>9</Month><Day>30</Day><Hour>6</Hour><Minute>37</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>9</Month><Day>30</Day><Hour>6</Hour><Minute>36</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>9</Month><Day>30</Day><Hour>4</Hour><Minute>15</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2025</Year><Month>9</Month><Day>27</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">41024792</ArticleId><ArticleId IdType="pmc">PMC12476781</ArticleId><ArticleId IdType="doi">10.4240/wjgs.v17.i9.109980</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Steinert AF, Rackwitz L, Gilbert F, N&#xf6;th U, Tuan RS. Concise review: the clinical application of mesenchymal stem cells for musculoskeletal regeneration: current status and perspectives. Stem Cells Transl Med. 2012;1:237&#x2013;247.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3659848</ArticleId><ArticleId IdType="pubmed">23197783</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu J, Gao J, Liang Z, Gao C, Niu Q, Wu F, Zhang L. Mesenchymal stem cells and their microenvironment. Stem Cell Res Ther. 2022;13:429.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9391632</ArticleId><ArticleId IdType="pubmed">35987711</ArticleId></ArticleIdList></Reference><Reference><Citation>Cui L, Wu Y, Cen L, Zhou H, Yin S, Liu G, Liu W, Cao Y. Repair of articular cartilage defect in non-weight bearing areas using adipose derived stem cells loaded polyglycolic acid mesh. Biomaterials. 2009;30:2683&#x2013;2693.</Citation><ArticleIdList><ArticleId IdType="pubmed">19217157</ArticleId></ArticleIdList></Reference><Reference><Citation>Barry F, Murphy M. Mesenchymal stem cells in joint disease and repair. Nat Rev Rheumatol. 2013;9:584&#x2013;594.</Citation><ArticleIdList><ArticleId IdType="pubmed">23881068</ArticleId></ArticleIdList></Reference><Reference><Citation>Taghizadeh RR, Cetrulo KJ, Cetrulo CL. Wharton's Jelly stem cells: future clinical applications. Placenta. 2011;32 Suppl 4:S311&#x2013;S315.</Citation><ArticleIdList><ArticleId IdType="pubmed">21733573</ArticleId></ArticleIdList></Reference><Reference><Citation>Bartolucci J, Verdugo FJ, Gonz&#xe1;lez PL, Larrea RE, Abarzua E, Goset C, Rojo P, Palma I, Lamich R, Pedreros PA, Valdivia G, Lopez VM, Nazzal C, Alcayaga-Miranda F, Cuenca J, Brobeck MJ, Patel AN, Figueroa FE, Khoury M. Safety and Efficacy of the Intravenous Infusion of Umbilical Cord Mesenchymal Stem Cells in Patients With Heart Failure: A Phase 1/2 Randomized Controlled Trial (RIMECARD Trial [Randomized Clinical Trial of Intravenous Infusion Umbilical Cord Mesenchymal Stem Cells on Cardiopathy]) Circ Res. 2017;121:1192&#x2013;1204.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6372053</ArticleId><ArticleId IdType="pubmed">28974553</ArticleId></ArticleIdList></Reference><Reference><Citation>Puglisi MA, Saulnier N, Piscaglia AC, Tondi P, Agnes S, Gasbarrini A. Adipose tissue-derived mesenchymal stem cells and hepatic differentiation: old concepts and future perspectives. Eur Rev Med Pharmacol Sci. 2011;15:355&#x2013;364.</Citation><ArticleIdList><ArticleId IdType="pubmed">21608430</ArticleId></ArticleIdList></Reference><Reference><Citation>Trounson A, Thakar RG, Lomax G, Gibbons D. Clinical trials for stem cell therapies. BMC Med. 2011;9:52.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3098796</ArticleId><ArticleId IdType="pubmed">21569277</ArticleId></ArticleIdList></Reference><Reference><Citation>Villeret F, Dharancy S, Erard D, Abergel A, Barbier L, Besch C, Boillot O, Boudjema K, Coilly A, Conti F, Corpechot C, Duvoux C, Faitot F, Faure S, Francoz C, Giostra E, Gugenheim J, Hardwigsen J, Hilleret MN, Hiriart JB, Houssel-Debry P, Kamar N, Lassailly G, Latournerie M, Pageaux GP, Samuel D, Vanlemmens C, Saliba F, Dumortier J. Liver transplantation for NAFLD cirrhosis: Age and recent coronary angioplasty are major determinants of survival. Liver Int. 2022;42:2428&#x2013;2441.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9804523</ArticleId><ArticleId IdType="pubmed">35924452</ArticleId></ArticleIdList></Reference><Reference><Citation>Gin&#xe8;s P, Krag A, Abraldes JG, Sol&#xe0; E, Fabrellas N, Kamath PS. Liver cirrhosis. Lancet. 2021;398:1359&#x2013;1376.</Citation><ArticleIdList><ArticleId IdType="pubmed">34543610</ArticleId></ArticleIdList></Reference><Reference><Citation>Mindikoglu AL, Pappas SC. New Developments in Hepatorenal Syndrome. Clin Gastroenterol Hepatol. 2018;16:162&#x2013;177.e1.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5831376</ArticleId><ArticleId IdType="pubmed">28602971</ArticleId></ArticleIdList></Reference><Reference><Citation>Shi M, Li YY, Xu RN, Meng FP, Yu SJ, Fu JL, Hu JH, Li JX, Wang LF, Jin L, Wang FS. Mesenchymal stem cell therapy in decompensated liver cirrhosis: a long-term follow-up analysis of the randomized controlled clinical trial. Hepatol Int. 2021;15:1431&#x2013;1441.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8651584</ArticleId><ArticleId IdType="pubmed">34843069</ArticleId></ArticleIdList></Reference><Reference><Citation>Li Z, Zhou X, Han L, Shi M, Xiao H, Lin M, Chi X. Human Umbilical Cord Blood-Derived Mesenchymal Stem Cell Transplantation for Patients with Decompensated Liver Cirrhosis. J Gastrointest Surg. 2023;27:926&#x2013;931.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10133084</ArticleId><ArticleId IdType="pubmed">36703021</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu WH, Song FQ, Ren LN, Guo WQ, Wang T, Feng YX, Tang LJ, Li K. The multiple functional roles of mesenchymal stem cells in participating in treating liver diseases. J Cell Mol Med. 2015;19:511&#x2013;520.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4369809</ArticleId><ArticleId IdType="pubmed">25534251</ArticleId></ArticleIdList></Reference><Reference><Citation>Christodoulou I, Goulielmaki M, Devetzi M, Panagiotidis M, Koliakos G, Zoumpourlis V. Mesenchymal stem cells in preclinical cancer cytotherapy: a systematic review. Stem Cell Res Ther. 2018;9:336.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6286545</ArticleId><ArticleId IdType="pubmed">30526687</ArticleId></ArticleIdList></Reference><Reference><Citation>Lan T, Luo M, Wei X. Mesenchymal stem/stromal cells in cancer therapy. J Hematol Oncol. 2021;14:195.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8596342</ArticleId><ArticleId IdType="pubmed">34789315</ArticleId></ArticleIdList></Reference><Reference><Citation>Matas J, Orrego M, Amenabar D, Infante C, Tapia-Limonchi R, Cadiz MI, Alcayaga-Miranda F, Gonz&#xe1;lez PL, Muse E, Khoury M, Figueroa FE, Espinoza F. Umbilical Cord-Derived Mesenchymal Stromal Cells (MSCs) for Knee Osteoarthritis: Repeated MSC Dosing Is Superior to a Single MSC Dose and to Hyaluronic Acid in a Controlled Randomized Phase I/II Trial. Stem Cells Transl Med. 2019;8:215&#x2013;224.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6392367</ArticleId><ArticleId IdType="pubmed">30592390</ArticleId></ArticleIdList></Reference><Reference><Citation>Lu Z, Zhu L, Liu Z, Wu J, Xu Y, Zhang CJ. IV/IT hUC-MSCs Infusion in RRMS and NMO: A 10-Year Follow-Up Study. Front Neurol. 2020;11:967.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7506071</ArticleId><ArticleId IdType="pubmed">33013641</ArticleId></ArticleIdList></Reference><Reference><Citation>Yin F, Wang WY, Jiang WH. Human umbilical cord mesenchymal stem cells ameliorate liver fibrosis in vitro and in vivo: From biological characteristics to therapeutic mechanisms. World J Stem Cells. 2019;11:548&#x2013;564.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6716089</ArticleId><ArticleId IdType="pubmed">31523373</ArticleId></ArticleIdList></Reference><Reference><Citation>Li T, Yan Y, Wang B, Qian H, Zhang X, Shen L, Wang M, Zhou Y, Zhu W, Li W, Xu W. Exosomes derived from human umbilical cord mesenchymal stem cells alleviate liver fibrosis. Stem Cells Dev. 2013;22:845&#x2013;854.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3585469</ArticleId><ArticleId IdType="pubmed">23002959</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang LT, Peng XB, Fang XQ, Li JF, Chen H, Mao XR. Human umbilical cord mesenchymal stem cells inhibit proliferation of hepatic stellate cells in vitro. Int J Mol Med. 2018;41:2545&#x2013;2552.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5846650</ArticleId><ArticleId IdType="pubmed">29484382</ArticleId></ArticleIdList></Reference><Reference><Citation>An SY, Jang YJ, Lim HJ, Han J, Lee J, Lee G, Park JY, Park SY, Kim JH, Do BR, Han C, Park HK, Kim OH, Song MJ, Kim SJ, Kim JH. Milk Fat Globule-EGF Factor 8, Secreted by Mesenchymal Stem Cells, Protects Against Liver Fibrosis in Mice. Gastroenterology. 2017;152:1174&#x2013;1186.</Citation><ArticleIdList><ArticleId IdType="pubmed">27956229</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen L, Zhang C, Chen L, Wang X, Xiang B, Wu X, Guo Y, Mou X, Yuan L, Chen B, Wang J, Xiang C. Human Menstrual Blood-Derived Stem Cells Ameliorate Liver Fibrosis in Mice by Targeting Hepatic Stellate Cells via Paracrine Mediators. Stem Cells Transl Med. 2017;6:272&#x2013;284.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5442725</ArticleId><ArticleId IdType="pubmed">28170193</ArticleId></ArticleIdList></Reference><Reference><Citation>Mohamadnejad M, Alimoghaddam K, Bagheri M, Ashrafi M, Abdollahzadeh L, Akhlaghpoor S, Bashtar M, Ghavamzadeh A, Malekzadeh R. Randomized placebo-controlled trial of mesenchymal stem cell transplantation in decompensated cirrhosis. Liver Int. 2013;33:1490&#x2013;1496.</Citation><ArticleIdList><ArticleId IdType="pubmed">23763455</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhao L, Chen S, Shi X, Cao H, Li L. A pooled analysis of mesenchymal stem cell-based therapy for liver disease. Stem Cell Res Ther. 2018;9:72.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5863358</ArticleId><ArticleId IdType="pubmed">29562935</ArticleId></ArticleIdList></Reference><Reference><Citation>Walczak P, Zhang J, Gilad AA, Kedziorek DA, Ruiz-Cabello J, Young RG, Pittenger MF, van Zijl PC, Huang J, Bulte JW. Dual-modality monitoring of targeted intraarterial delivery of mesenchymal stem cells after transient ischemia. Stroke. 2008;39:1569&#x2013;1574.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2857730</ArticleId><ArticleId IdType="pubmed">18323495</ArticleId></ArticleIdList></Reference><Reference><Citation>Kidd S, Spaeth E, Dembinski JL, Dietrich M, Watson K, Klopp A, Battula VL, Weil M, Andreeff M, Marini FC. Direct evidence of mesenchymal stem cell tropism for tumor and wounding microenvironments using in vivo bioluminescent imaging. Stem Cells. 2009;27:2614&#x2013;2623.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4160730</ArticleId><ArticleId IdType="pubmed">19650040</ArticleId></ArticleIdList></Reference><Reference><Citation>Kimura K, Kanto T, Shimoda S, Harada K, Kimura M, Nishikawa K, Imamura J, Ogawa E, Saio M, Ikura Y, Okusaka T, Inoue K, Ishikawa T, Ieiri I, Kishimoto J, Todaka K, Kamisawa T. Safety, tolerability, and anti-fibrotic efficacy of the CBP/&#x3b2;-catenin inhibitor PRI-724 in patients with hepatitis C and B virus-induced liver cirrhosis: An investigator-initiated, open-label, non-randomised, multicentre, phase 1/2a study. EBioMedicine. 2022;80:104069.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9126795</ArticleId><ArticleId IdType="pubmed">35605429</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang J, Shen H, Xu J, Liu L, Tan J, Li M, Xu N, Luo S, Wang J, Yang F, Tang J, Li Q, Wang Y, Yu L, Yan Z. Liver-Targeted siRNA Lipid Nanoparticles Treat Hepatic Cirrhosis by Dual Antifibrotic and Anti-inflammatory Activities. ACS Nano. 2020;14:6305&#x2013;6322.</Citation><ArticleIdList><ArticleId IdType="pubmed">32378877</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>